Eli Lilly and Co (NYSE: LLY). Meaningful positive changes in fundamentals have recently occurred: the consensus estimate for December, 2024 increased significantly, significant quarterly sales acceleration occurred, and the consensus estimate for December, 2025 increased significantly.
Significant positive changes in investment behavior have recently occurred for Eli Lilly and Co (NYSE: LLY): the stock’s recent price rise disrupted its longer term downtrend.
In light of these very positive signals we are reviewing our current Overall Rating of B. We would continue to view the shares with optimism pending completion of this review in the next several days.
Current PriceTarget Research Rating
Reflecting future returns on capital that are forecasted to exceed the cost of capital, LLY is expected to continue to be a major Value Builder.
Eli Lilly has a current Value Trend Rating of B (Positive). The Value Trend Rating reflects inconsistent signals from PTR’s two proprietary measures of a stock’s attractiveness. Eli Lilly has a neutral Appreciation Score of 49 but a very high Power Rating of 92, with the Positive Value Trend Rating the result.
Recent Price Action
On 9/11/24, Eli Lilly and Co (NYSE: LLY) stock enjoyed a large increase of 2.2%, closing at $920.89. However, trading volume in this advance was below average at 82% of normal. Relative to the market the stock has been exceptionally strong over the last nine months but has declined -3.7% during the last week.
Be the first to comment